Dr Roberto Salgado
Roberto Salgado is board certified in Anatomical Pathology since 2006. After his graduation as an Anatomical Pathologist he worked, besides as a clinical pathologist, also as a consultant Pathologist for the Breast International Group (BIG), and as a member of the Aurora Working Group helped develop the Aurora Molecular Screening Program for Metastatic Breast Cancer Patients. He was also a member of the Aurora Molecular Advisory Board of the Breast International Group. He’s a scientific collaborator of the Immuno-Task Force of the Breast International Group and an Honorary Research Fellow at the Division of Research at the Peter Mac Callum Cancer Center, Melbourne, Australia. Currently he’s chairing an International Consortium of Pathologists, namely the “International Immuno-Oncology Biomarkers Working Group that develops guidelines for the assessment of Immuno-Oncological Biomarkers in cancer. His strategic views on Oncology have been published in major international high impact factor journals including Nature Reviews Clinical Oncology, Nature Reviews Drug Discovery and Lancet Oncology. He has specific expertise in the Molecular Pathology of solid tumours, validation of biomarkers, innovative clinical trials incorporating genomics and development of biomarkers in immunotherapeutic trials, with a focus on Tumor Infiltrating Lymphocytes (TILs), with publications in Lancet Oncology, Nature, Nature Medicine and Journal of Clinical Oncology.